PolyPid Ltd. Company Profile
NASDAQ: PYPDHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
PolyPid at a glance
PolyPid Ltd. (NASDAQ: PYPD) is a Biotechnology company in the Healthcare sector headquartered in Petah Tikva, Israel. PolyPid is led by Ms. Dikla Czaczkes Akselbrad and employs about 69 people. The company's shares have traded publicly since 2020.
At a market capitalization of $100.5 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001611842, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does PolyPid do?
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Business description based on the company's public filings.
Company information
- Legal name
- PolyPid Ltd.
- Ticker
- NASDAQ: PYPD
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ms. Dikla Czaczkes Akselbrad
- Employees
- 69
- Headquarters
- 18 Hasivim Street, Petah Tikva, Israel
- Phone
- 972 7 4719 5700
- Website
- polypid.com
- IPO year
- 2020
- Market cap
- $100.54M
- SEC CIK
- 0001611842
Companies similar to PolyPid
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KZIAKazia Therapeutics Limited ADR | 8.82 | -5.06% | $100.79M | vs PYPD |
| ANIXAnixa Biosciences Inc. | 2.91 | -1.36% | $101.16M | vs PYPD |
| PLYXPolaryx Therapeutics Inc. | 2.00 | -4.31% | $99.69M | vs PYPD |
| CRBPCorbus Pharmaceuticals Holdings Inc. | 5.27 | -4.01% | $101.93M | vs PYPD |
| BMEABiomea Fusion Inc. | 1.37 | +3.79% | $99.05M | vs PYPD |
| AARDAardvark Therapeutics Inc. | 4.71 | -5.04% | $103.08M | vs PYPD |
| IMUXImmunic Inc. | 7.56 | -0.92% | $103.15M | vs PYPD |
| BDTXBlack Diamond Therapeutics Inc. | 1.81 | -1.09% | $103.72M | vs PYPD |